NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

DNTH

Dianthus Therapeutics Inc

Jul 03 • 02:32PM ET

18.85

Dollar change +0.47
Percentage change 2.56	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BIIB GILD AMGN MRNA BMY LLY PFE ABBV

| Held by: VTI IWM XBI VXF IWN VTWO SCHA AVSC IWC ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.89	Insider Own	30.61%	Shs Outstand	32.13M	Perf Week	3.97%
Market Cap	606.22M	Forward P/E	-	EPS next Y	-3.57	Insider Trans	0.00%	Shs Float	22.32M	Perf Month	7.16%
Enterprise Value	344.39M	PEG	-	EPS next Q	-0.87	Inst Own	96.23%	Short Float	29.96%	Perf Quarter	5.54%
Income	-100.73M	P/S	92.98	EPS this Y	-30.86%	Inst Trans	12.28%	Short Ratio	20.94	Perf Half Y	-12.33%
Sales	6.52M	P/B	1.84	EPS next Y	-6.86%	ROA	-27.56%	Short Interest	6.69M	Perf YTD	-13.53%
Book/sh	10.23	P/C	2.30	EPS next 5Y	-15.32%	ROE	-28.73%	52W High	32.27 -41.59%	Perf Year	-34.71%
Cash/sh	8.18	P/FCF	-	EPS past 3/5Y	50.25% 40.14%	ROIC	-30.55%	52W Low	13.36 41.04%	Perf 3Y	-2.63%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	93.29%	Volatility	6.16% 6.32%	Perf 5Y	-85.12%
Dividend TTM	-	EV/Sales	52.82	EPS Y/Y TTM	51.03%	Oper. Margin	-1796.40%	ATR (14)	1.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.99	Sales Y/Y TTM	189.31%	Profit Margin	-1544.02%	RSI (14)	54.08	Recom	1.15
Dividend Gr. 3/5Y	- -	Current Ratio	15.99	EPS Q/Q	-53.91%	SMA20	3.82%	Beta	1.42	Target Price	51.05
Payout	-	Debt/Eq	0.00	Sales Q/Q	33.07%	SMA50	-0.98%	Rel Volume	0.32	Prev Close	18.38
Employees	78	LT Debt/Eq	0.00	Earnings	May 12 AMC	SMA200	-15.91%	Avg Volume	319.30K	Price	18.85
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.47% 44.13%	Trades		Volume	101,602	Change	2.56%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-02-25	Initiated	William Blair	Outperform
Dec-20-24	Initiated	TD Cowen	Buy
Oct-03-24	Initiated	Oppenheimer	Outperform	$48
Jul-26-24	Initiated	Robert W. Baird	Outperform	$58
Jun-27-24	Initiated	Cantor Fitzgerald	Overweight
May-16-24	Initiated	H.C. Wainwright	Buy	$40
Feb-15-24	Initiated	Stifel	Buy	$44
Dec-26-23	Initiated	Jefferies	Buy	$22
Nov-22-23	Initiated	Wedbush	Outperform	$23
Oct-30-23	Initiated	Guggenheim	Buy	$45
Sep-28-23	Initiated	Raymond James	Outperform	$24
Aug-25-22	Downgrade	Goldman	Buy → Neutral	$2
Jan-06-22	Upgrade	Goldman	Neutral → Buy	$7 → $8
Aug-20-21	Resumed	Goldman	Neutral	$7
Aug-03-21	Downgrade	JP Morgan	Overweight → Neutral	$16 → $7
Jul-22-21	Reiterated	B. Riley Securities	Buy	$21 → $19
Jun-29-21	Initiated	Cantor Fitzgerald	Overweight	$20
Jun-15-21	Initiated	BTIG Research	Buy	$20
May-18-21	Initiated	B. Riley Securities	Buy	$21
Jan-07-21	Initiated	Mizuho	Buy	$16

Show Previous Ratings

Jun-21-25 03:50PM	Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside (Insider Monkey)
May-29-25 07:00AM	Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-25 04:10PM	Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors (GlobeNewswire)
May-12-25 05:10PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.18%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
05:35PM	Loading…
May-07-25 05:35PM	Emergent Biosolutions (EBS) Q1 Earnings Top Estimates (Zacks)
May-05-25 07:00AM	Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September (GlobeNewswire)
Apr-29-25 07:00AM	Dianthus Therapeutics to Participate in Two Upcoming Investor Events (GlobeNewswire)
Apr-23-25 02:53PM	Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead (Seeking Alpha)
Apr-03-25 10:03AM	Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
Mar-24-25 09:57AM	Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? (Zacks)
Mar-11-25 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results (GlobeNewswire) -6.33%
Mar-05-25 07:00AM	Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors (GlobeNewswire) +14.60%
Feb-26-25 07:00AM	Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) -6.32%
Jan-30-25 07:00AM	Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Jan-08-25 07:00AM	Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-07-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results (GlobeNewswire)
Nov-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-15-24 07:00AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting (GlobeNewswire) +8.30%
Sep-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September (GlobeNewswire)
Aug-08-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results (GlobeNewswire)
Jul-08-24 11:06AM	Dianthus (DNTH) Gains 18% in the Past Month: Here's Why (Zacks) +11.93%
Jun-28-24 11:30AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) (GlobeNewswire)
Jun-12-24 07:00AM	Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN) (GlobeNewswire) +5.01%
May-30-24 04:30PM	Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -6.59%
May-09-24 10:56PM	DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
May-08-24 04:30PM	Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference (GlobeNewswire)
May-03-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.46% -7.29%
Apr-11-24 07:30AM	Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire) +9.11%
04:30PM	Loading…
Apr-05-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.02%
Mar-21-24 10:54PM	DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +14.32%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results (GlobeNewswire)
Mar-07-24 04:30PM	Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-24 07:00AM	Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG) (GlobeNewswire)
Feb-23-24 08:00AM	Dianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-31-24 04:05PM	Dianthus Therapeutics to Participate at the Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire) +9.05%
Jan-22-24 07:30AM	Dianthus Therapeutics Announces $230 Million Private Placement (GlobeNewswire) +37.24%
Jan-02-24 08:30AM	Dianthus Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.10%
Dec-14-23 07:04AM	DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023 (InvestorPlace)
Nov-29-23 04:05PM	Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Nov-09-23 04:05PM	Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results (GlobeNewswire)
Sep-14-23 05:04PM	Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc (GuruFocus.com)
Aug-14-23 01:35PM	CEO of shuttered biotech Magenta Therapeutics makes leap to Flagship startup (American City Business Journals)
May-03-23 04:19PM	Magenta Sets Up Dianthus Merger After Stopping Blood Cancer Trial Due To Patient Death (Benzinga) -14.29%
07:00AM	Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement (GlobeNewswire)
Mar-31-23 04:10PM	Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan (GlobeNewswire)
06:09AM	The Zacks Analyst Blog Highlights Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics (Zacks)
Mar-27-23 10:20AM	Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-09-23 01:24PM	On eve of shutdown, Cambridge biotech loses 84% of staff, including 5 execs (American City Business Journals)
10:13AM	Magenta's CEO Leaves After Patient Death Halts Trials, Shuttering Concerns Looms (Benzinga)
Feb-03-23 01:35PM	Magenta Therapeutics to shut down after patient death (American City Business Journals) +51.66%
Feb-02-23 04:05PM	Magenta Therapeutics to Explore Strategic Alternatives (GlobeNewswire)
05:58AM	The Petri Dish: Departed White House adviser returns to the Broad (American City Business Journals)
Jan-25-23 04:05PM	Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety (GlobeNewswire) +6.89% -11.09%
Dec-21-22 07:39AM	Magenta (MGTA) Down on Pipeline Update for Leukemia Drug (Zacks) -7.64%
Dec-20-22 11:20AM	Magenta Therapeutics Shares Crashes As Dose-Limiting Toxicities Observed In Lead Blood Cancer Study (Benzinga) -52.71%
09:00AM	Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial (GlobeNewswire)
Dec-13-22 05:56AM	Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting (Benzinga) -7.83%
Dec-12-22 04:30PM	Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates (GlobeNewswire)
08:00AM	Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial (GlobeNewswire)
Nov-03-22 09:01AM	Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
09:01AM	Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights (GlobeNewswire)
Nov-01-22 08:00AM	Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference (GlobeNewswire)
Oct-17-22 12:16PM	We Think Magenta Therapeutics (NASDAQ:MGTA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-23-22 09:15AM	Australian Billionaire Kerr Neilson is Selling These 15 Stocks (Insider Monkey)
Aug-17-22 08:00AM	Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors (GlobeNewswire)
Aug-04-22 08:00AM	Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights (GlobeNewswire)
Aug-02-22 08:00AM	Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-17-22 09:04AM	How Much Of Magenta Therapeutics, Inc. (NASDAQ:MGTA) Do Institutions Own? (Simply Wall St.)
May-16-22 12:29PM	Magenta Therapeutics Reveals Encouraging Interim Data From Lowest Dose Of MGTA-117 In Leukemia Trial (Benzinga)
09:35AM	After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA) (Zacks)
08:00AM	Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights (Business Wire)
May-10-22 11:54AM	Here's Why We're Watching Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation (Simply Wall St.)
Apr-14-22 04:41PM	Stem cell startup cuts staff by 14% (American City Business Journals) -7.05% -14.29%
12:15PM	Magenta Therapeutics Trims R&D, Cuts Workforce (Benzinga)
08:00AM	Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway (Business Wire)
Mar-08-22 08:00AM	Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights (Business Wire) +7.06%
Mar-03-22 08:00AM	Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference (Business Wire)
Feb-07-22 09:35AM	What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares? (Simply Wall St.)
Jan-18-22 07:00AM	Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform (GlobeNewswire)
Jan-10-22 08:00AM	Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022 (Business Wire)
Jan-05-22 08:00AM	Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference (Business Wire) -6.50%
Dec-14-21 09:00AM	Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting (Business Wire)
Nov-10-21 06:20AM	Big Pharma Is Going Holiday Shopping. Who's Next? (Motley Fool)
Nov-08-21 09:24AM	Companies Like Magenta Therapeutics (NASDAQ:MGTA) Are In A Position To Invest In Growth (Simply Wall St.) -6.36%
Nov-04-21 09:10AM	Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights (Business Wire)
09:09AM	Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting (Business Wire)
Oct-04-21 08:00AM	Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer (Business Wire)
Sep-21-21 08:00AM	Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference (Business Wire)
Sep-15-21 08:00AM	Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial (Business Wire) +8.16%
Aug-09-21 06:20AM	How Much Of Magenta Therapeutics, Inc. (NASDAQ:MGTA) Do Institutions Own? (Simply Wall St.)
Aug-05-21 08:00AM	Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights (Business Wire)
Aug-03-21 05:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (PR Newswire) -10.97%
08:00AM	Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August (Business Wire)
Aug-01-21 11:50AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (Newsfile)
Jul-30-21 09:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (ACCESSWIRE)
11:14AM	Were Hedge Funds Right About Magenta Therapeutics, Inc. (MGTA)? (Insider Monkey)
Jul-28-21 07:39PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (PR Newswire)
Jul-26-21 08:16PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (GlobeNewswire)

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DNTH

Dianthus Therapeutics Inc

Upgrade your FINVIZ experience